765 related articles for article (PubMed ID: 29384841)
1. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
[TBL] [Abstract][Full Text] [Related]
2. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis.
Al Afif A; Williams BA; Rigby MH; Bullock MJ; Taylor SM; Trites J; Hart RD
Thyroid; 2015 Sep; 25(9):1008-12. PubMed ID: 26161997
[TBL] [Abstract][Full Text] [Related]
3. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
4. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.
Qu N; Zhang L; Wu WL; Ji QH; Lu ZW; Zhu YX; Lin DZ
Tumour Biol; 2016 Jul; 37(7):8783-9. PubMed ID: 26743781
[TBL] [Abstract][Full Text] [Related]
5. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma.
Kim HJ; Sohn SY; Jang HW; Kim SW; Chung JH
World J Surg; 2013 Feb; 37(2):376-84. PubMed ID: 23135422
[TBL] [Abstract][Full Text] [Related]
6. The impact of the multifocality and subtypes of papillary thyroid carcinoma on central compartment lymph node metastasis.
Soylu L; Aydin OU; Ozbas S; Bilezikci B; Ilgan S; Gursoy A; Kocak S
Eur Rev Med Pharmacol Sci; 2016 Oct; 20(19):3972-3979. PubMed ID: 27775804
[TBL] [Abstract][Full Text] [Related]
7. Lymph node metastasis characteristics of papillary thyroid carcinoma located in the isthmus: A single-center analysis.
Li G; Lei J; Peng Q; Jiang K; Chen W; Zhao W; Li Z; Gong R; Wei T; Zhu J
Medicine (Baltimore); 2017 Jun; 96(24):e7143. PubMed ID: 28614242
[TBL] [Abstract][Full Text] [Related]
8. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.
Tam AA; Özdemir D; Çuhacı N; Başer H; Aydın C; Yazgan AK; Ersoy R; Çakır B
Endocrine; 2016 Sep; 53(3):774-83. PubMed ID: 27090526
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
10. Multifocality Is not an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score-Matching Analysis.
Geron Y; Benbassat C; Shteinshneider M; Or K; Markus E; Hirsch D; Levy S; Ziv-Baran T; Muallem-Kalmovich L
Thyroid; 2019 Apr; 29(4):513-522. PubMed ID: 30799769
[TBL] [Abstract][Full Text] [Related]
11. Incidence and clinical characteristics of prelaryngeal lymph node metastasis in papillary thyroid cancer.
Lee YC; Shin SY; Kwon KH; Eun YG
Eur Arch Otorhinolaryngol; 2013 Sep; 270(9):2547-50. PubMed ID: 23553243
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
Xu S; Huang H; Huang Y; Qian J; Wang X; Xu Z; Liu S; Liu J
JAMA Surg; 2023 Jan; 158(1):73-79. PubMed ID: 36449303
[TBL] [Abstract][Full Text] [Related]
13. Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer.
Barczyński M; Konturek A; Stopa M; Nowak W
Langenbecks Arch Surg; 2014 Feb; 399(2):237-44. PubMed ID: 24213969
[TBL] [Abstract][Full Text] [Related]
14. Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.
Feng JW; Pan H; Wang L; Ye J; Jiang Y; Qu Z
J Endocrinol Invest; 2020 May; 43(5):601-613. PubMed ID: 31749082
[TBL] [Abstract][Full Text] [Related]
15. High-risk factors for lymph node metastasis in contralateral central compartment in unilateral papillary thyroid carcinoma（cT1N0）.
Zhou B; Qin J
Eur J Surg Oncol; 2021 Apr; 47(4):882-887. PubMed ID: 33092967
[TBL] [Abstract][Full Text] [Related]
16. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
17. Pathological multifocality is not a prognosis factor of papillary thyroid carcinoma: a single-center, retrospective study.
Omi Y; Haniu K; Kamio H; Fujimoto M; Yoshida Y; Horiuchi K; Okamoto T
World J Surg Oncol; 2022 Dec; 20(1):394. PubMed ID: 36510206
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma.
Feng JW; Yang XH; Wu BQ; Sun DL; Jiang Y; Qu Z
Clin Transl Oncol; 2019 Nov; 21(11):1482-1491. PubMed ID: 30879178
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of lymphocytic thyroiditis coexistent with papillary thyroid carcinoma].
Wang SX; She ZQ; An CM; Zhang XW; Li ZJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 51(4):277-81. PubMed ID: 27095720
[TBL] [Abstract][Full Text] [Related]
20. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer.
Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
Medicine (Baltimore); 2018 Dec; 97(51):e13435. PubMed ID: 30572443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
